Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03011814 · ClinicalTrials.gov registry record · Phase 1
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
A Phase 1 study of Sezary Syndrome and Recurrent Mycosis Fungoides, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 4
- Study locations
NCT03011814 is a Phase 1 study of Sezary Syndrome and Recurrent Mycosis Fungoides that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 38 participants, below the 80-participant average among 13 other Sezary Syndrome trials with a reported enrollment target (52% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03011814, a Phase 1 study of Sezary Syndrome and Recurrent Mycosis Fungoides, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 4
- Study locations
Study Summary
This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab and lenalidomide may work better in treating patients with cutaneous or peripheral T cell lymphoma.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- OTHER Laboratory Biomarker Analysis
- DRUG Lenalidomide
Study Locations (4)
California
- City of Hope Medical Center - Duarte
New York
- Memorial Sloan-Kettering Cancer Center - New York
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-03-08 |
| Est. Completion | 2026-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03011814
The ClinicalTrials.gov registry entry for NCT03011814 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 80-participant average among 13 other Sezary Syndrome trials with a reported enrollment target (52% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Sezary Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Durvalumab is the first listed.
NCT03011814 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03011814 about?
NCT03011814 is a clinical study titled "Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma". This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durva...
What is the current status of trial NCT03011814?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2017-03-08. Estimated completion is 2026-08-30.
What conditions does trial NCT03011814 study?
This clinical trial studies the following conditions: Sezary Syndrome, Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Folliculotropic Mycosis Fungoides.
What interventions are being tested in trial NCT03011814?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT03011814?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03011814 being conducted?
This trial has 4 study locations across California, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sezary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
ACTIVE NOT RECRUITING · Phase 1
-
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
ACTIVE NOT RECRUITING · Phase 1
-
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
COMPLETED · Phase 1
-
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
RECRUITING
-
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
RECRUITING · Phase 2
-
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.